Previous 10 | Next 10 |
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will participate in the following investor conferences: Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:10 a.m. ET at the Boston Marriott Copley Place ...
Summary Pharmaceuticals and biotechnology still look attractive. Healthcare providers are close to their baseline in both valuation and quality. I look at iShares Genomics Immunology and Healthcare ETF, an ETF in genomics and immunology. 10 stocks cheaper than their peers in Nov...
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2022 Earnings Conference Call February 16, 2023, 08:30 ET Company Participants Matt Roache - Director, IR Thomas McCourt - CEO & Director Michael Shetzline - Chief Medical Officer, SVP and Head, Research & Drug Developme...
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation
Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q4 Non-GAAP EPS of $0.27 beats by $0.01 . Revenue of $107.2M (-8.5% Y/Y) misses by $1.02M . For FY23, expected revenue is $420 to $435 million, vs. consensus of $426.65M. U.S. LINZESS Net Sales Growth of...
– 2022 GAAP and non-GAAP net income of $175 million – – 2022 adjusted EBITDA of $252 million; ended 2022 with $656 million in cash and cash equivalents – – FDA granted priority review to the sNDA for LINZESS® (linaclotide) for the treatm...
The U.S. Food and Drug Administration (FDA) granted priority review to AbbVie ( NYSE: ABBV ) and Ironwood Pharmaceuticals' ( NASDAQ: IRWD ) application seeking expanded approval of Linzess (linaclotide) to treat children and adolescents aged six years to 17 years with functio...
– FDA assigns 2 nd Quarter 2023 target action date – – If approved, LINZESS would be the first and only FDA-approved prescription therapy for functional constipation in this patient population – – Functional constipation affects an estimated ...
In stock investing, it's easy to focus on big names and blue-chip companies since they are frequently reported in financial media. Conversely, smaller companies, but with promising businesses, tend to be ignored. The latter have smaller market capitalizations and usually trade at more affordable ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 16, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...